Novo Nordisk is a leading global healthcare company headquartered in Denmark that has been making innovative medicines for more than 100 years with leading positions within diabetes care, obesity care, hemophilia care, and growth hormone therapy. Their purpose is to drive change to defeat serious chronic diseases, built upon their heritage in diabetes. To fulfil their company purpose, they pioneer scientific breakthroughs, expand access to their medicines, and work to prevent and cure disease.
The company is steadfast in its conviction to stay focused, think long term, and do business in a financially, socially, and environmentally responsible way. With U.S. headquarters in New Jersey and production and research facilities in seven states, Novo Nordisk employs nearly 6,000 people throughout the country.
Innovation
Novo Nordisk R&D is dedicated to collaborating for the future of innovative medicines. The company has more than 600 scientists and engineers developing and managing a global R&D program that explores novel and innovative treatments to address the unmet needs of people living with diabetes, obesity, hemophilia, growth hormone-related disorders, and non-alcoholic steatohepatitis (NASH).
Novo Nordisk collaborates with Valo Health to develop novel treatments for cardiometabolic diseases based on Valo’s Opal Computational Platform™ large human dataset and computation powered by AI. The AI platform drives small molecule discovery, and the Biowire® human tissue modelling platform speeds up the discovery and development process.
Talent Development
As a company owned by the Novo Nordisk Foundation, one of the world’s largest independent charitable enterprises, Novo Nordisk prioritizes contributing to scientific, humanitarian, and social causes in an equitable way.
Novo Nordisk’s Employee Resource Groups (ERGs) drive efforts to foster a sense of belonging and build a more diverse, equitable, and inclusive workplace. These groups enhance the work experience and professional development for many Novo Nordisk employees, and ultimately help retain and recruit a more diverse workforce to better serve patients and communities.
Social Responsibility
Novo Nordisk and UNICEF partner to help prevent global childhood overweight and obesity, now adding camps to their offerings. Over the next three years, Novo Nordisk will commit $8 million to scale and accelerate efforts to create healthier environments for children through policy implementation and innovations that enable children to eat well, play, and be physically active. The aim is to positively impact at least 10 million children.
Novo Nordisk implemented a global zero environmental impact strategy called “Circular for Zero” which is focused on: circular company (reducing the production of waste sent to landfill and zero loss of water, energy, and resources); circular supply (reducing the environmental impact across the supply chain by collaborating with suppliers to encourage circular business practices and increasing use of recycled and carbon-neutral materials and resources); and circular products (upgrading existing products and designing new products based on circular principles as well as work toward a sustainable solution for the reuse and recycling of products).
